TuftsCSDD-Logo-Color.jpg
Drug Companies Still Under Pressure to Increase Pace of Development, According to Tufts Center for the Study of Drug Development
January 06, 2010 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 6, 2010) - Although drug developers are improving R&D efficiency, in part by terminating more unpromising drugs earlier in development, their continued success...
Information Builders Helps Poudre Valley Health System Achieve Operational Excellence
January 06, 2010 08:30 ET | Information Builders
NEW YORK, NY--(Marketwire - January 6, 2010) - Grappling with healthcare costs that are rising six to seven percent every year, leading hospitals are using business intelligence (BI) technology to...
TuftsCSDD-Logo-Color.jpg
New Products to Treat Neglected Diseases Are on the Rise, According to Tufts Center for the Study of Drug Development
November 17, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 17, 2009) - New products to treat neglected diseases have received marketing approval from regulatory agencies at a steadily increasing rate in recent years as...
TuftsCSDD-Logo-Color.jpg
Top Performing Drug Developers Are Merging Operational and Strategic Objectives, According to Tufts Center for the Study of Drug Development
October 30, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 30, 2009) - Drug companies racing to develop new products to replace drugs coming off patent are finding that success is increasingly tied to the company's ability...
TuftsCSDD-Logo-Color.jpg
Marketing Exclusivity for First-in-Class Drugs Has Shortened to 2.5 Years, According to Tufts Center for the Study of Drug Development
September 09, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 9, 2009) - Marketing exclusivity periods for first-in-class drugs have fallen dramatically in recent decades -- from a median of 10.2 years in the 1970s to 2.5...
TuftsCSDD-Logo-Color.jpg
Large Pharmaceutical Firms Are Getting More Drugs Into Development While Terminating Unpromising Candidates, According to Tufts Center for the Study of Drug Development
July 22, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 22, 2009) - Large pharmaceutical firms, under pressure to bring new medicines to market faster, have been getting more drug candidates into development in recent years...
TuftsCSDD-Logo-Color.jpg
New Drug R&D Increasingly Depends on Partnerships Between Drug Sponsors and Service Providers, According to Tufts Center for the Study of Drug Development
July 08, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 8, 2009) - If drug developers are to remain competitive, they must rely less on traditional outsourcing, in which external service providers offer a way to quickly...
TuftsCSDD-Logo-Color.jpg
Number of Therapeutic Peptides in Clinical Study Has Nearly Doubled Since the 1990s, According to Tufts Center for the Study of Drug Development
May 20, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 20, 2009) - Since 2000, the number of therapeutic peptides in clinical study has nearly doubled the 1990s rate, due in part to advances in synthesis, delivery, and...
TuftsCSDD-Logo-Color.jpg
Pharmaceutical Licensing Success Is Tied to Clarity of Strategy on Both Sides, According to Tufts Center for the Study of Drug Development
April 16, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - April 16, 2009) - Pharmaceutical firms looking to license new drug candidates from other firms will improve their chances of achieving a successful alliance if they focus on...
TuftsCSDD-Logo-Color.jpg
Three-Quarters of U.S. Health Plans Reimburse for Off-Label Uses of Prescription Drugs, According to Tufts Center for the Study of Drug Development
March 10, 2009 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 10, 2009) - Reflecting recent rapid growth of off-label prescribing of prescription drugs, 75 percent of all health plans in the United States now reimburse patients...